Lundbeck A/S will use technology from Norak to screen another cell line for possible drug development, Norak said Tuesday.
Financial details were not disclosed. Lundbeck exercised an option to use Norak’s Transflour technology. The process targets so-called G protein-coupled receptors, which are among the most lucrative drug targets.
Norak: www.norakbio.com
